US-based clinical research organisation INC Research has integrated and consolidated its consultancy services with the launch of a new global business unit, INC Research Strategic Advisory Services.
The new unit offers biopharmaceutical companies integrated expertise in drug development and commercialisation, regulatory consulting and submissions, and quality assurance.
It comprises three practice areas:
• AVOS Consulting, INC Research’s strategic management consulting division, providing independent perspectives on the future business environment for healthcare products and services.
• Regulatory Consulting and Submissions – regulatory expertise across the entire lifecycle of small molecules, proteins (including biosimilars) and medical devices.
• Compliance Consulting – working with customers as an extension of their own quality assurance department, including scheduling; preparing for and conducting audits; preparing and finalising audit reports; reviewing audit responses and reconciliation; and issuing audit certificates.
“Working as an integrated team gives our expert advisors better visibility into our customers’ product development lifecycles and needs, enabling a true strategic partnership to evolve,” said Tim Dietlin, INC Research’s senior vice president, Global Consulting and Strategic Alliances, and head of the new unit.
